gallium-68-labeled prostate-specific membrane antigen (68ga-psma) uptake in renal cell carcinoma and lung adenocarcinoma: a case report

Gallium-68-labeled prostate-specific membrane antigen (68ga-psma), as a relatively new positron emission tomography (pet) radiotracer, can be used to evaluate tumors other than prostate cancer, including renal cell carcinoma and probably non-small cell lung cancer, as discussed in our case. we present the case of a 65-year-old man with a history of lung adenocarcinoma diagnosed in 2015 and a subsequent diagnosis of renal cell carcinoma in 2018, treated with a right lower lobectomy and a left partial nephrectomy, respectively. both conditions were evaluated using 18f-fluorodeoxyglucose (18f-fdg) pet/computed tomography (ct) scan before surgery. a rise in prostate-specific antigen (psa) was detected in the follow-up in september 2020, and the patient was referred for a 68ga-psma pet/ct scan following pelvic magnetic resonance imaging (mri). the 68ga-psma pet/ct scan demonstrated avid lesions in both lung and kidney surgical beds. the 68ga-psma pet/ct scan can be potentially used in patients with recurrent renal cell carcinoma to detect metastasis. this modality may also detect non-small cell lung cancer lesions; however, further investigation is needed.